 Catherine Demers
Concepts (200)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| White Matter | 3 | 2024 | 153 | 1.520 |
Why?
| | Mothers | 3 | 2025 | 765 | 0.720 |
Why?
| | Heart Failure | 6 | 2024 | 2324 | 0.520 |
Why?
| | Amygdala | 3 | 2022 | 198 | 0.490 |
Why?
| | Arachidonic Acids | 1 | 2016 | 43 | 0.460 |
Why?
| | Corticotropin-Releasing Hormone | 1 | 2016 | 72 | 0.450 |
Why?
| | Endocannabinoids | 1 | 2016 | 57 | 0.440 |
Why?
| | Hair | 2 | 2024 | 86 | 0.400 |
Why?
| | Anxiety | 2 | 2024 | 1122 | 0.390 |
Why?
| | Pregnancy Complications | 4 | 2025 | 586 | 0.390 |
Why?
| | Diffusion Tensor Imaging | 2 | 2024 | 75 | 0.380 |
Why?
| | Hydrocortisone | 2 | 2024 | 297 | 0.360 |
Why?
| | Home Care Services | 1 | 2015 | 280 | 0.350 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2016 | 2137 | 0.340 |
Why?
| | Longitudinal Studies | 5 | 2025 | 2942 | 0.320 |
Why?
| | Pregnancy | 13 | 2025 | 7122 | 0.290 |
Why?
| | Prenatal Exposure Delayed Effects | 3 | 2024 | 641 | 0.260 |
Why?
| | Brain | 5 | 2024 | 2934 | 0.260 |
Why?
| | Magnetic Resonance Imaging | 8 | 2025 | 3888 | 0.260 |
Why?
| | Stroke Volume | 3 | 2024 | 650 | 0.240 |
Why?
| | Anhedonia | 1 | 2025 | 17 | 0.230 |
Why?
| | Depression | 4 | 2025 | 1561 | 0.230 |
Why?
| | Fathers | 1 | 2025 | 51 | 0.230 |
Why?
| | Object Attachment | 1 | 2025 | 48 | 0.220 |
Why?
| | Corpus Striatum | 2 | 2025 | 179 | 0.220 |
Why?
| | Anisotropy | 1 | 2024 | 75 | 0.210 |
Why?
| | Limbic System | 1 | 2024 | 55 | 0.210 |
Why?
| | Nucleus Accumbens | 1 | 2025 | 135 | 0.210 |
Why?
| | Flavins | 1 | 2023 | 4 | 0.210 |
Why?
| | Gestational Age | 2 | 2024 | 980 | 0.200 |
Why?
| | Models, Psychological | 1 | 2025 | 297 | 0.200 |
Why?
| | Luciferases | 1 | 2023 | 152 | 0.200 |
Why?
| | Depression, Postpartum | 1 | 2025 | 123 | 0.200 |
Why?
| | Female | 27 | 2025 | 78304 | 0.190 |
Why?
| | Psychotherapy, Brief | 1 | 2023 | 41 | 0.190 |
Why?
| | Postpartum Period | 1 | 2025 | 368 | 0.180 |
Why?
| | Infant | 4 | 2025 | 10023 | 0.180 |
Why?
| | Signal Transduction | 1 | 2016 | 5185 | 0.180 |
Why?
| | Birth Weight | 1 | 2024 | 506 | 0.170 |
Why?
| | Self Report | 1 | 2025 | 869 | 0.170 |
Why?
| | Humans | 30 | 2025 | 144671 | 0.160 |
Why?
| | Social Behavior | 2 | 2013 | 287 | 0.160 |
Why?
| | Sleep | 2 | 2024 | 890 | 0.160 |
Why?
| | Adult | 16 | 2025 | 40489 | 0.150 |
Why?
| | Child Development | 1 | 2024 | 482 | 0.150 |
Why?
| | Prospective Studies | 5 | 2023 | 7994 | 0.150 |
Why?
| | Emotions | 1 | 2024 | 578 | 0.150 |
Why?
| | Racism | 1 | 2021 | 155 | 0.150 |
Why?
| | Psychoses, Substance-Induced | 1 | 2019 | 15 | 0.140 |
Why?
| | Infant, Newborn | 8 | 2025 | 6399 | 0.140 |
Why?
| | Gray Matter | 1 | 2019 | 92 | 0.140 |
Why?
| | Premature Birth | 1 | 2022 | 376 | 0.140 |
Why?
| | Stress, Psychological | 3 | 2017 | 1148 | 0.140 |
Why?
| | Genetic Predisposition to Disease | 2 | 2019 | 2350 | 0.140 |
Why?
| | Male | 20 | 2025 | 72431 | 0.140 |
Why?
| | Sex Characteristics | 2 | 2013 | 776 | 0.130 |
Why?
| | Atrial Fibrillation | 1 | 2023 | 555 | 0.120 |
Why?
| | Mental Disorders | 1 | 2025 | 1154 | 0.120 |
Why?
| | Frontal Lobe | 1 | 2017 | 159 | 0.120 |
Why?
| | Polyunsaturated Alkamides | 1 | 2016 | 8 | 0.120 |
Why?
| | Marijuana Abuse | 1 | 2019 | 210 | 0.120 |
Why?
| | Receptors, Corticotropin-Releasing Hormone | 1 | 2016 | 28 | 0.120 |
Why?
| | Amidohydrolases | 1 | 2016 | 32 | 0.120 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2023 | 919 | 0.120 |
Why?
| | Genome-Wide Association Study | 2 | 2019 | 1374 | 0.110 |
Why?
| | Perception | 1 | 2017 | 376 | 0.110 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2025 | 1742 | 0.110 |
Why?
| | Hypertension | 1 | 2023 | 1262 | 0.100 |
Why?
| | Receptors, AMPA | 1 | 2015 | 148 | 0.100 |
Why?
| | Pregnancy Trimester, Third | 2 | 2024 | 114 | 0.100 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2016 | 539 | 0.100 |
Why?
| | Touch | 1 | 2013 | 39 | 0.100 |
Why?
| | Maternal Behavior | 1 | 2013 | 83 | 0.090 |
Why?
| | Cost-Benefit Analysis | 1 | 2015 | 638 | 0.090 |
Why?
| | Impulsive Behavior | 1 | 2013 | 143 | 0.090 |
Why?
| | Cocaine-Related Disorders | 1 | 2013 | 133 | 0.090 |
Why?
| | Self Concept | 1 | 2013 | 256 | 0.090 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2016 | 779 | 0.080 |
Why?
| | Cardiac Catheterization | 3 | 2023 | 557 | 0.080 |
Why?
| | Genotype | 1 | 2016 | 1847 | 0.080 |
Why?
| | Oxygen | 1 | 2016 | 984 | 0.080 |
Why?
| | Young Adult | 4 | 2025 | 14122 | 0.080 |
Why?
| | Self Care | 1 | 2013 | 389 | 0.080 |
Why?
| | Ventricular Function, Left | 2 | 2023 | 536 | 0.080 |
Why?
| | Behavior, Animal | 1 | 2013 | 521 | 0.070 |
Why?
| | Chronic Disease | 1 | 2015 | 1810 | 0.070 |
Why?
| | Dalteparin | 1 | 2008 | 10 | 0.070 |
Why?
| | Siblings | 2 | 2019 | 195 | 0.060 |
Why?
| | Cognitive Dysfunction | 1 | 2013 | 464 | 0.060 |
Why?
| | Opioid-Related Disorders | 1 | 2015 | 601 | 0.060 |
Why?
| | Pregnancy Outcome | 3 | 2024 | 479 | 0.060 |
Why?
| | Caudate Nucleus | 1 | 2025 | 21 | 0.060 |
Why?
| | Putamen | 1 | 2025 | 22 | 0.060 |
Why?
| | Psychopathology | 1 | 2025 | 55 | 0.060 |
Why?
| | Intention to Treat Analysis | 1 | 2025 | 79 | 0.060 |
Why?
| | Mother-Child Relations | 1 | 2025 | 132 | 0.050 |
Why?
| | Organ Size | 1 | 2025 | 461 | 0.050 |
Why?
| | Cardiologists | 1 | 2024 | 47 | 0.050 |
Why?
| | Safety-net Providers | 1 | 2025 | 128 | 0.050 |
Why?
| | Reward | 1 | 2025 | 245 | 0.050 |
Why?
| | Heart Atria | 1 | 2023 | 141 | 0.050 |
Why?
| | Retrospective Studies | 2 | 2023 | 17149 | 0.050 |
Why?
| | Canada | 1 | 2023 | 432 | 0.040 |
Why?
| | Telomere Shortening | 1 | 2022 | 19 | 0.040 |
Why?
| | Placenta | 1 | 2008 | 781 | 0.040 |
Why?
| | Psychometrics | 1 | 2025 | 731 | 0.040 |
Why?
| | Ventricular Remodeling | 1 | 2023 | 275 | 0.040 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2024 | 392 | 0.040 |
Why?
| | Angina, Unstable | 1 | 2000 | 82 | 0.040 |
Why?
| | Enoxaparin | 1 | 2000 | 68 | 0.040 |
Why?
| | Heparin | 1 | 2000 | 243 | 0.040 |
Why?
| | Physician-Patient Relations | 1 | 2024 | 589 | 0.040 |
Why?
| | Interview, Psychological | 1 | 2019 | 94 | 0.040 |
Why?
| | Telomere | 1 | 2022 | 290 | 0.030 |
Why?
| | Neuropsychological Tests | 2 | 2013 | 1134 | 0.030 |
Why?
| | Diseases in Twins | 1 | 2019 | 115 | 0.030 |
Why?
| | Calcitriol | 2 | 1995 | 57 | 0.030 |
Why?
| | Sex Factors | 1 | 2024 | 2104 | 0.030 |
Why?
| | Cholecalciferol | 2 | 1995 | 60 | 0.030 |
Why?
| | Fibrinolytic Agents | 1 | 2000 | 290 | 0.030 |
Why?
| | Middle Aged | 5 | 2024 | 35971 | 0.030 |
Why?
| | Hippocampus | 1 | 2022 | 966 | 0.030 |
Why?
| | Thrombocythemia, Essential | 1 | 1996 | 6 | 0.030 |
Why?
| | Pregnancy Complications, Hematologic | 1 | 1996 | 24 | 0.030 |
Why?
| | Telemedicine | 1 | 2025 | 957 | 0.030 |
Why?
| | Steroid Hydroxylases | 1 | 1995 | 19 | 0.030 |
Why?
| | Clinical Competence | 1 | 2024 | 1237 | 0.030 |
Why?
| | Prognosis | 1 | 2024 | 4312 | 0.030 |
Why?
| | Habituation, Psychophysiologic | 1 | 2015 | 58 | 0.030 |
Why?
| | Interferon-alpha | 1 | 1996 | 194 | 0.030 |
Why?
| | Vitamin D Deficiency | 2 | 1995 | 187 | 0.030 |
Why?
| | Mice, Inbred Strains | 1 | 2015 | 396 | 0.030 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 1995 | 161 | 0.030 |
Why?
| | Cross-Sectional Studies | 2 | 2019 | 5870 | 0.030 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 1995 | 268 | 0.030 |
Why?
| | Intestine, Small | 1 | 1995 | 167 | 0.030 |
Why?
| | Risk Assessment | 1 | 2024 | 3729 | 0.030 |
Why?
| | Species Specificity | 1 | 2015 | 573 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 3 | 2013 | 2521 | 0.020 |
Why?
| | Secondary Prevention | 2 | 2008 | 255 | 0.020 |
Why?
| | Judgment | 1 | 2013 | 66 | 0.020 |
Why?
| | Receptors, Dopamine | 1 | 2013 | 19 | 0.020 |
Why?
| | Hypocalcemia | 1 | 1993 | 38 | 0.020 |
Why?
| | Tyrosine 3-Monooxygenase | 1 | 2013 | 72 | 0.020 |
Why?
| | Receptor, Serotonin, 5-HT2A | 1 | 2013 | 18 | 0.020 |
Why?
| | Primary Health Care | 1 | 2023 | 1730 | 0.020 |
Why?
| | Myocardial Infarction | 1 | 2000 | 1209 | 0.020 |
Why?
| | Video Recording | 1 | 2013 | 217 | 0.020 |
Why?
| | Task Performance and Analysis | 1 | 2013 | 198 | 0.020 |
Why?
| | Alcohol Drinking | 1 | 2019 | 827 | 0.020 |
Why?
| | Calcium | 2 | 1995 | 1182 | 0.020 |
Why?
| | Nerve Tissue Proteins | 1 | 2015 | 590 | 0.020 |
Why?
| | Communication Barriers | 1 | 2013 | 130 | 0.020 |
Why?
| | Quality of Life | 1 | 2023 | 3183 | 0.020 |
Why?
| | RNA, Messenger | 3 | 2013 | 2815 | 0.020 |
Why?
| | Aged | 3 | 2024 | 25955 | 0.020 |
Why?
| | Rats | 3 | 2013 | 5570 | 0.020 |
Why?
| | Child | 2 | 2022 | 22600 | 0.020 |
Why?
| | Brain Mapping | 1 | 2013 | 535 | 0.020 |
Why?
| | Recurrence | 1 | 2013 | 1136 | 0.020 |
Why?
| | Obesity | 1 | 2023 | 3070 | 0.020 |
Why?
| | Residence Characteristics | 1 | 2013 | 374 | 0.020 |
Why?
| | Cerebral Cortex | 1 | 2013 | 470 | 0.020 |
Why?
| | ErbB Receptors | 1 | 1993 | 632 | 0.020 |
Why?
| | Registries | 1 | 2019 | 2392 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2015 | 1159 | 0.020 |
Why?
| | Executive Function | 1 | 2013 | 460 | 0.020 |
Why?
| | Fetal Death | 1 | 2008 | 58 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2023 | 11735 | 0.020 |
Why?
| | Infant, Low Birth Weight | 1 | 2008 | 154 | 0.020 |
Why?
| | Patient Care Team | 1 | 2013 | 690 | 0.020 |
Why?
| | Pre-Eclampsia | 1 | 2008 | 203 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2013 | 3603 | 0.010 |
Why?
| | Age Factors | 1 | 2013 | 3329 | 0.010 |
Why?
| | Animals | 4 | 2015 | 37948 | 0.010 |
Why?
| | Cognition | 1 | 2013 | 1263 | 0.010 |
Why?
| | Liver | 1 | 1993 | 1889 | 0.010 |
Why?
| | Mass Screening | 1 | 2013 | 1348 | 0.010 |
Why?
| | Risk Factors | 1 | 2019 | 10796 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2013 | 2591 | 0.010 |
Why?
| | Pilot Projects | 1 | 2008 | 1886 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2013 | 8284 | 0.010 |
Why?
| | Injections, Intravenous | 1 | 2000 | 198 | 0.010 |
Why?
| | Myocardial Revascularization | 1 | 2000 | 84 | 0.010 |
Why?
| | Injections, Subcutaneous | 1 | 2000 | 168 | 0.010 |
Why?
| | Adolescent | 1 | 2019 | 22409 | 0.010 |
Why?
| | Vitamin D3 24-Hydroxylase | 1 | 1995 | 16 | 0.010 |
Why?
| | DNA Probes | 1 | 1995 | 58 | 0.010 |
Why?
| | Enzyme Induction | 1 | 1995 | 88 | 0.010 |
Why?
| | Double-Blind Method | 1 | 2000 | 2033 | 0.010 |
Why?
| | Blotting, Northern | 1 | 1995 | 203 | 0.010 |
Why?
| | Incidence | 1 | 2000 | 2892 | 0.010 |
Why?
| | Transforming Growth Factor alpha | 1 | 1993 | 55 | 0.010 |
Why?
| | Down-Regulation | 1 | 1995 | 616 | 0.010 |
Why?
| | Epidermal Growth Factor | 1 | 1993 | 161 | 0.010 |
Why?
| | Aspirin | 1 | 1996 | 402 | 0.010 |
Why?
| | Analysis of Variance | 1 | 1995 | 1301 | 0.010 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 1996 | 496 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2000 | 5414 | 0.010 |
Why?
| | Phosphorylation | 1 | 1993 | 1704 | 0.000 |
Why?
|
|
Demers's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|